CoChat

Oral Semaglutide

Open access
Hughes, Sally, Neumiller, Joshua J. · 2020 · Clinical Diabetes
Cited by 63

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Oral semaglutide (Rybelsus) is the first oral glucagon-like peptide 1 (GLP-1) receptor agonist product approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2diabetes (1). As a class, GLP-1 receptor agonists are widely used and recommended for the management of type 2 diabetes. The American Diabetes Association’s Standards of Medical Care in Diabetes—2019 recommend GLP-1 receptor agonists with proven cardiovascular benefit as one of the two preferred options for add-on therapy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease after metformin and lifestyle intervention (2). Drugs in this class are likewise generally recommended as add-on therapy after metformin in patients not meeting individualized glycemic goals when there is a compelling need to minimize hypoglycemia or promote weight loss (2).Despite their clinical benefits,GLP-1 receptoragonists historically have required self-administration by subcutaneous injection. The availability of oral semaglutide provides a new option within the class for patients who are unable or unwilling to self-administer an injectable agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/cd19-0079

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Hughes, S., & Neumiller, J. J.
Venue
Clinical Diabetes
Published
2020-01-01
Volume
38
Issue
1
Pages
109-111
ISSN
  • 0891-8929 (ISSN-L)
  • 1945-4953
OpenAlex
W4251262166
Cited by
63
References
5
FWCI
1.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.